Bruker (BRKR) Jefferies 2024 Global Healthcare Conference summary

Innovation highlights and product launches

• Launched three new mass spectrometry systems and key workflow consumables at ASMS, including the timsTOF Ultra 2, advancing single-cell and subcellular proteomics capabilities.

• Innovations in mass spectrometry imaging now enable spatial multi-omics, detecting proteins, peptides, lipids, metabolites, and glycans.

• Over 1,000 timsTOF instruments are now in customer hands, reflecting strong global sales momentum.

• New factory in Bremen, Germany, has doubled manufacturing capacity for mass spectrometry products.

• Factory expected to become a billion-dollar mass spectrometry facility over several years.

M&A strategy and integration

• Spent $1.5 billion in six months on acquisitions, focusing on strategic assets in single-cell and spatial biology.

• Acquisitions of PhenomeX and NanoString accelerated entry into spatial biology, saving years of organic development.

• Smaller bolt-on acquisitions have enabled rapid product launches and reduced R&D timelines by several years.

• Integration is distributed across business groups, leveraging strong management teams for smoother execution.

• Swift restructuring actions taken with acquired companies, including significant cost reductions at PhenomeX.

Financial outlook and growth

• Project Accelerate 2.0 has driven three years of double-digit organic growth, with 2024 guidance at 5%-7%.

• Revenue expected to reach $3.4 billion in 2024, with a midterm outlook of $4.3 billion by 2027.

• EPS growth projected at over 15% through 2027, despite short-term dilution from acquisitions.

• Core business remains strong, supporting continued investment and integration of new assets.